ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01277315
Recruitment Status : Unknown
Verified January 2011 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
First Posted : January 14, 2011
Last Update Posted : February 28, 2011
Sponsor:
Collaborator:
Max Planck Institute for Infection Biology
Information provided by:
Charite University, Berlin, Germany

January 13, 2011
January 14, 2011
February 28, 2011
February 2011
June 2012   (Final data collection date for primary outcome measure)
  • Number and Severity of adverse events (AE) [ Time Frame: 1 month ]
  • Number and Severity of serious adverse events (SAE) [ Time Frame: 1 month ]
  • Number and Severity of adverse drug reactions (ARD) [ Time Frame: 1 month ]
  • Number and Severity of unexpected adverse drug reactions (UADR) [ Time Frame: 1 month ]
  • Number and Severity of serious adverse drug reactions (SADR) [ Time Frame: 1 month ]
  • Number and Severity of suspected unexpected serious adverse reaction (SUSAR) [ Time Frame: 1 month ]
  • Pathological laboratory parameters [ Time Frame: 1 month ]
Same as current
Complete list of historical versions of study NCT01277315 on ClinicalTrials.gov Archive Site
Long Term Tolerability and Safety of Anakinra in ALS Patients [ Time Frame: 1 month ]
Same as current
Not Provided
Not Provided
 
Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis
Open Safety and Tolerability Trial to Evaluate a Subcutaneous Injection Solution of 100 mg of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon. As a result of motor neurodegeneration, a progredient paralysis of the extremities and of the speaking, swallowing, and breathing musculature develops. ALS leads to death by respiratory insufficiency in a mean course of 3-5 years. So far, Riluzole is the only approved neuroprotective medication which effects a slight lifespan prolongation of 1.5 - 2.5 months. Riluzole inhibits the presynaptic glutamate release and lowers the level of glutamate liberated by activated microglia.

The researchers propose an investigational therapy of ALS with subcutaneous administration of 100 mg of Anakinra. The neuronal inflammation is a crucial pathogenetic factor of the motor neuron degeneration. Inflammatory processes are detectable in sporadic ALS, in the autosomal-dominant form of ALS and in transgenic mouse model. The rationale of this clinical trial is based on the anti-inflammatory effect of Anakinra. One of the key mediators of inflammatory response is Interleukin-1. Anakinra is a recombinant produced Interleukin-1 receptor antagonist. This gives Anakinra anti-inflammatory attributes that presumably reduce motor neuron degeneration and disease progression.

Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Amyotrophic Lateral Sclerosis (ALS)
Drug: Anakinra
Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
Not Provided
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R, Meissner F, Molawi K, Münch C, Holm T, Meyer R, Meyer T, Zychlinsky A. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study. PLoS One. 2015 Oct 7;10(10):e0139684. doi: 10.1371/journal.pone.0139684. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
20
Same as current
Not Provided
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients between 18 and 80 years of age
  • Clinical diagnosis of amyotrophic lateral sclerosis with predominant affection of the lower motor neuron or the clinical ALS variant of progressive muscular atrophy (PMA)
  • Clinical signs of lower motor neuron degeneration in at least one anatomic region beyond the brain stem
  • Sporadic and familial ALS
  • Onset of paresis six months to four years before study inclusion
  • Treatment with riluzol 100mg/d at least 1 month before study inclusion

Exclusion Criteria:

  • Diagnosis of amyotrophic lateral sclerosis with predominant affection or the upper motor neuron without clinical signs of a concurrent affection of the lower motor neuron in at least one anatomic region beyond the brain stem (spastic ALS) - Diagnosis of primary lateral sclerosis (PLS)
  • Patients with known intolerance to anakinra, riluzol or one of the additives
  • Clinically severe hypoventilation syndrome with vital capacity < 50%
  • Pregnancy or breastfeeding
  • Continuous non-invasive ventilation with ventilator-free time < 2 hours - Tracheotomy and mechanical ventilation
  • Laboratory parameters outside the normal range that correspond to a clinically severe cardiovascular, pulmological, hematological, hepatological, metabolic or renal disease
  • Malignancies
  • Severe renal insufficiency (creatinine clearance < 30 ml/min)
  • History of recurrent infections or a disease that may predispose to infections
  • Severe neutropenia (absolute neutrophil count < 1.5 x 109/l)
  • Monoclonal gammopathy of unknown significance
  • Infections including infections with HIV and hepatitis B and C
  • Dementia and unable to give informed consent
  • History of epilepsy and epileptic seizures
  • Contraindication to E coli-derived proteins, anakinra or any components of the product
  • Concurrent therapy of anakinra and etanercept or other TNF blocking agents
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01277315
ANA-ALS01
No
Not Provided
Not Provided
Charité University, Berlin, Germany, Charité Universitätsmedizin, Berlin, Germany
Charite University, Berlin, Germany
Max Planck Institute for Infection Biology
Principal Investigator: Thomas Meyer, MD Charité University Hospital, Berlin, Germany
Charite University, Berlin, Germany
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP